Careful consideration when responding to new data: dolutegravir and pregnancy
File(s)1530869019jve-4-208.pdf (29.1 KB)
Published version
Author(s)
Foster, Caroline
Fidler, sarah
Lyall, E
Taylor, GP
Type
Journal Article
Abstract
This case highlights the current complexities of managing women in the early stages of pregnancy presenting on dolutegravir-based regimens. When responding to new data, there is an important decision to be made, between the potential, uncertain risk of teratogenicity against the potential increased risk of in utero vertical transmission of HIV-1.
Date Issued
2018-07-01
Date Acceptance
2018-06-30
Citation
Journal of virus eradication, 2018, 4, pp.208-208
ISSN
2055-6640
Publisher
Mediscript Ltd
Start Page
208
End Page
208
Journal / Book Title
Journal of virus eradication
Volume
4
Copyright Statement
© 2018 The Authors.
Journal of Virus Eradication
published by Mediscript Ltd
This is an open access article published under the terms of a Creative Commons License.
Journal of Virus Eradication
published by Mediscript Ltd
This is an open access article published under the terms of a Creative Commons License.
Sponsor
Imperial College Healthcare NHS Trust- BRC Funding
Imperial College Healthcare NHS Trust- BRC Funding
Grant Number
RDA02 79560
RDA02
Subjects
Science & Technology
Life Sciences & Biomedicine
Infectious Diseases
dolutegravir
pregnancy
treatment switch
dolutegravir, pregnancy, treatment switch
Publication Status
Published